Search
forCommunity 10 of 75
- New warning by FDA on topical finasteride
- Just FYI, Here are pictures of 6 months results on Clascoterone 5%. Is it remarkable? No. But it seems likely to be FDA approved considering 1% is already available. This is a win, especially if you pair it with other treatments like Finasteride.
- Dutasteride would have been approved for AGA by the US FDA.
- Finasteride alternative close to fda approval in the US
- Peeps who arent able to get gains even after using fda approved meds
- Following the recent IPO and the positive Phase 3 clinical data for VDPHL01 (extended-release oral minoxidil), what is the projected timeline for the FDA submission and the subsequent commercial availability on the market?
- FDA Policy Shift Explained: What It Actually Means for PP405, VDPHL-01, Breezula and Hair Loss Drug Timelines
- There’s actually a quite good chance that next year, we might see a new treatment get FDA approval for the first time in nearly three decades.
- Good news for stem cells hair therapies - US federal judge: using patients' stem cells does NOT fall under FDA jurisdiction
- US FDA will now default to only one clinical trial for drug applications, will this accelerate the release of PP405 and other drugs in clinical trials?
Research 10 of 1000+
- Assessment of biotin supplementation among patients in an outpatient dermatology clinic
- Synthetic hair implantations continue; serious complications result
- Synthetic hair implantations continue; serious complications result
- Biotin beware: Perils of biotin supplementation: Response to: “The epidemiology, impact, and diagnosis of micronutrient nutritional dermatoses. Part 2: B-complex vitamins”
- Global online interest in finasteride sexual side effects
- Global Online Interest in Finasteride Sexual Side Effects
- MP44-04 TRENDS IN 5-ALPHA REDUCTASE INHIBITOR USE BEFORE AND AFTER THE FOOD AND DRUG ADMINISTRATION SAFETY WARNING
- US Food and Drug Administration Warning Regarding Finasteride and Suicidal Ideation: What Should Urologists Know?
- How routine pharmacovigilance failed to identify finasteride’s persistent sexual side effects
- Drug related lipid metabolism abnormalities: a real-world pharmacovigilance exploratory analysis based on U.S. FDA adverse event reporting system (FAERS)